367 related articles for article (PubMed ID: 28540607)
21. Safety and efficacy of long-term etanercept in the treatment of methotrexate-refractory polyarticular-course juvenile idiopathic arthritis in Japan.
Mori M; Takei S; Imagawa T; Imanaka H; Nerome Y; Higuchi R; Kawano Y; Yokota S; Sugiyama N; Yuasa H; Fletcher T; Wajdula JS
Mod Rheumatol; 2012 Sep; 22(5):720-6. PubMed ID: 22212889
[TBL] [Abstract][Full Text] [Related]
22. Dynamics of serum levels of TNF-α in a longitudinal follow-up study in 98 patients with juvenile idiopathic arthritis treated with anti-TNF-α biological drugs.
Morozova N; Avramovič MZ; Markelj G; Toplak N; Avčin T
Clin Rheumatol; 2024 Jul; 43(7):2287-2293. PubMed ID: 38775868
[TBL] [Abstract][Full Text] [Related]
23. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis.
Lamot L; Bukovac LT; Vidovic M; Frleta M; Harjacek M
Clin Exp Rheumatol; 2011; 29(1):131-9. PubMed ID: 21345300
[TBL] [Abstract][Full Text] [Related]
24. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents.
Russo RA; Katsicas MM
J Rheumatol; 2009 May; 36(5):1078-82. PubMed ID: 19435972
[TBL] [Abstract][Full Text] [Related]
25. A combination of etanercept and methotrexate for the treatment of refractory juvenile idiopathic arthritis: a pilot study.
Schmeling H; Mathony K; John V; Keysser G; Burdach S; Horneff G
Ann Rheum Dis; 2001 Apr; 60(4):410-2. PubMed ID: 11247875
[TBL] [Abstract][Full Text] [Related]
26. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
[TBL] [Abstract][Full Text] [Related]
27. Uveitis Events During Adalimumab, Etanercept, and Methotrexate Therapy in Juvenile Idiopathic Arthritis: Data From the Biologics in Pediatric Rheumatology Registry.
Foeldvari I; Becker I; Horneff G
Arthritis Care Res (Hoboken); 2015 Nov; 67(11):1529-35. PubMed ID: 25988824
[TBL] [Abstract][Full Text] [Related]
28. Increasing the etanercept dose in a treat-to-target approach in juvenile idiopathic arthritis: does it help to reach the target? A post-hoc analysis of the BeSt for Kids randomised clinical trial.
van Dijk BT; Bergstra SA; van den Berg JM; Schonenberg-Meinema D; van Suijlekom-Smit LWA; van Rossum MAJ; Koopman-Keemink Y; Ten Cate R; Allaart CF; Brinkman DMC; Hissink Muller PCE
Pediatr Rheumatol Online J; 2024 May; 22(1):53. PubMed ID: 38730442
[TBL] [Abstract][Full Text] [Related]
29. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
[TBL] [Abstract][Full Text] [Related]
30. Etanercept treatment for children with refractory juvenile idiopathic arthritis.
Kuo HC; Yu HR; Wu CC; Chang LS; Yang KD
J Microbiol Immunol Infect; 2011 Feb; 44(1):52-6. PubMed ID: 21531353
[TBL] [Abstract][Full Text] [Related]
31. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab.
Horneff G; Klein A; Klotsche J; Minden K; Huppertz HI; Weller-Heinemann F; Kuemmerle-Deschner J; Haas JP; Hospach A
Arthritis Res Ther; 2016 Nov; 18(1):272. PubMed ID: 27881144
[TBL] [Abstract][Full Text] [Related]
32. Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis.
Khraishi M; Millson B; Woolcott J; Jones H; Marshall L; Ruperto N
Pediatr Rheumatol Online J; 2019 Sep; 17(1):64. PubMed ID: 31500631
[TBL] [Abstract][Full Text] [Related]
33. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis.
Swart JF; van Dijkhuizen EHP; Wulffraat NM; de Roock S
Ann Rheum Dis; 2018 Mar; 77(3):336-342. PubMed ID: 29138257
[TBL] [Abstract][Full Text] [Related]
34. Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate.
Lovell DJ; Brunner HI; Reiff AO; Jung L; Jarosova K; Němcová D; Mouy R; Sandborg C; Bohnsack JF; Elewaut D; Gabriel C; Higgins G; Kone-Paut I; Jones OY; Vargová V; Chalom E; Wouters C; Lagunes I; Song Y; Martini A; Ruperto N
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665432
[TBL] [Abstract][Full Text] [Related]
35. A follow-up study of patients with juvenile idiopathic arthritis who discontinued etanercept due to disease remission.
Pratsidou-Gertsi P; Trachana M; Pardalos G; Kanakoudi-Tsakalidou F
Clin Exp Rheumatol; 2010; 28(6):919-22. PubMed ID: 21205467
[TBL] [Abstract][Full Text] [Related]
36. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
Otten MH; Prince FH; Armbrust W; ten Cate R; Hoppenreijs EP; Twilt M; Koopman-Keemink Y; Gorter SL; Dolman KM; Swart JF; van den Berg JM; Wulffraat NM; van Rossum MA; van Suijlekom-Smit LW
JAMA; 2011 Dec; 306(21):2340-7. PubMed ID: 22056397
[TBL] [Abstract][Full Text] [Related]
37. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
Alexeeva EI; Namazova-Baranova LS; Bzarova TM; Valieva SI; Denisova RV; Sleptsova TV; Isaeva KB; Chomahidze AM; Taibulatov NI; Fetisova AN; Karaseva AV; Baranov AA
Pediatr Rheumatol Online J; 2017 Jun; 15(1):51. PubMed ID: 28615036
[TBL] [Abstract][Full Text] [Related]
38. Vitamin D receptor gene polymorphism influences lipid profile in patients with juvenile idiopathic arthritis.
Bašić J; Vojinović J; Jevtović-Stoimenov T; Despotović M; Sušić G; Lazarević D; Milošević V; Cvetković M; Pavlović D
Clin Rheumatol; 2019 Jan; 38(1):117-124. PubMed ID: 30128913
[TBL] [Abstract][Full Text] [Related]
39. Predictors of Flare Following Etanercept Withdrawal in Patients with Rheumatoid Factor-negative Juvenile Idiopathic Arthritis Who Reached Remission while Taking Medication.
Aquilani A; Marafon DP; Marasco E; Nicolai R; Messia V; Perfetti F; Magni-Manzoni S; De Benedetti F
J Rheumatol; 2018 Jul; 45(7):956-961. PubMed ID: 29717035
[TBL] [Abstract][Full Text] [Related]
40. Medically Significant Infections Are Increased in Patients With Juvenile Idiopathic Arthritis Treated With Etanercept: Results From the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
Davies R; Southwood TR; Kearsley-Fleet L; Lunt M; Hyrich KL;
Arthritis Rheumatol; 2015 Sep; 67(9):2487-94. PubMed ID: 25989609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
